The History and Evolution of the Clinical Effectiveness of Haemophilia Type A Treatment: A Systematic Review
Tóm tắt
Từ khóa
Tài liệu tham khảo
Oldenburg J, Dolan G, Lemm G (2009) Haemophilia care then, now and in the future. Haemophilia 15(Suppl 1):2–7
Stachnik J (2010) Hemophilia: etiology, complications, and current options in management. Formul J 45:218–227
Wong T, Recht M (2011) Current options and new developments in the treatment of haemophilia. Drugs 71(3):305–320
Evatt BL (2006) The tragic history of AIDS in the hemophilia population, 1982–1984. J Thromb Haemost 4(11):2295–2301
Mannucci PM (2003) AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. J Thromb Haemost 1(10):2065–2069
Chorba TL, Holman RC, Strine TW, Clarke MJ, Evatt BL (1994) Changes in longevity and causes of death among persons with hemophilia A. Am J Hematol 45(2):112–121
Ragni MV, Tegtmeier GE, Levy JA, Kaminsky LS, Lewis JH, Spero JA et al (1986) AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations. Blood 67(3):592–595
Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio MA et al (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362(9377):22–29
Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K et al (2003) Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362(9392):1267–1274
Makris M, Garson JA, Ring CJ, Tuke PW, Tedder RS, Preston FE (1993) Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood 81(7):1898–1902
Van der Poel CL, Reesink HW, Mauser-Bunschoten EP, Kaufmann RH, Leentvaar-Kuypers A, Chamuleau RA et al (1991) Prevalence of anti-HCV antibodies confirmed by recombinant immunoblot in different population subsets in The Netherlands. Vox Sang 61(1):30–36
Mannucci PM, Tuddenham EG (2001) The hemophilias–from royal genes to gene therapy. N Engl J Med 344(23):1773–1779
Prabhu R (2010) Novel strategies to improve recombinant factor VIII production and its in vivo recovery. Indian J Hematol Blood Transfus 26(3):124–125
Berntorp E, Astermark J, Bjormarkman VS, Blanchette K, Fisher K (2003) Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 9(Suppl 1):1–4
Franchini M, Coppola A, Molinari AC, Santoro S, Schinco V, Speciale V, Tagliaferri A (2009) Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Haemophilia 15(2):578–586
Berntorp E (2009) Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Haemophilia 15(6):1219–1227
Santagostino E, Mancuso ME (2008) Prevention of arthropathy in haemophilia: prophylaxis. Haemophilia 14(Suppl 6):16–19
Petrini P (2007) Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 13(Suppl 2):16–22
Royal S, Schramm W, Bertntorp E, Giagrande A, Gringeri A, Ludlam C, Kronker B, Szucs T (2002) Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 8(1):44–50
Carcao MD, Aledort LM (2007) The round table group “Prophylaxis in the haemophilia population-optimizing therapy”. Haemophilia 13(3):227–232
Dunn AL (2005) Management and prevention of recurrent hemarthrosis in patients with hemophilia. Curr Opin Hematol 12(5):390–394
Feldman BM (2006) Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 4(6):1228–1236
Carcao M, Chambost H, Ljung R (2010) Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies. Haemophilia 16(Suppl 2):4–9
Valentino L (2009) Controversies regarding the prophylactic management of adults with severe haemophilia A. Haemophilia 15(Suppl 2):5–22
Valentino L (2004) Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia 10(2):147–157
Dimichele D, Rivard G, Hay A, Antunes S (2004) Inhibitors in haemophilia: clinical aspects. Haemophilia 10(Suppl 4):140–145
Miners A (2009) Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A. Haemophilia 15(4):881–887
Carcao M, Lambert T (2010) Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia 16(Suppl 2):16–23
Lloyd M, Wight JS, Paisley S, Night C (2003) Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 9(4):464–520
Dimichele D (2007) Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. J Thromb Haemost 5(Suppl 1):143–150
Gouw SC, van der Bom JG, Marijke van den Berg H (2007) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109(11):4648–4654
Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian T, Calvez T (2006) Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107(1):46–51
Darby SC, Keeling DM, Spooner RJ, Wan KS, Giangrande PL, Collins PW, Hill FG, Hay CR (2004) The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–1999. J Thromb Haemost 2(7):1047–1054
Tusell J, Perez-Bianco R (2002) Prophylaxis in developed and in emerging countries. Haemophilia 8(3):183–188
Von Depka M (2005) Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety. Haemophilia 9(Suppl 1):18–23
Astermark J, Santagostino E, Wk Hoots (2010) Clinical issues in inhibitors. Haemophilia 16(Suppl 5):54–60
Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lssitchkov T, Rusen L, Serban (2007) Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 5(9):1904–1913
Hoots WK, Ebbesen LS, Konkle BA, Auerswald GK, Roberts HR, Weatherall J et al (2008) Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 14(3):466–475
Wight J, Paisley S, Knight C (2003) Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 9(4):436–463
Aleem A, Saidu A, Abdulkarim H, Al-Diab AR, Al-Sagheer A, Qayum A et al (2009) Rituximab as a single agent in the management of adult patients with haemophilia A and inhibitors: marked reduction in inhibitor level and clinical improvement in bleeding but failure to eradicate the inhibitor. Haemophilia 15(1):210–216